A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
Latest Information Update: 01 Jan 2024
At a glance
- Drugs Peginterferon lambda-1a (Primary)
- Indications Hepatitis D
- Focus Therapeutic Use
- Acronyms LIMT; LIMT HDV; LIMT-1
- Sponsors Eiger BioPharmaceuticals
- 14 Nov 2023 Results of pooled analysis from LOWR-3 , LIMT-1 and LIFT-1, comparing different combinations of novel HDV therapies and assessing their anti-HDV effectiveness, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Nov 2023 Results assessing the predict Lambda mechanisms of action and efficacy using mathematical modeling of measured HDV RNA, ALT and HBsAg kinetics, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 20 Feb 2023 Results assessing the safety and efficacy of Lambda monotherapy in patients with chronic hepatitis delta virus, published in the Hepatology.